ZURICH, Aug 4 (Reuters) - Novartis NOVN.S CAR-T cell therapy Kymriah met its primary endpoint at an interim analysis of a phase-II trial in patients with relapsed or refractory follicular lymphoma, the Swiss drugmaker said on Tuesday. ID:nGNE4ySMhY
Findings of the ELARA trial will support regulatory submissions, with filing in the United States anticipated in 2021 and in the European Union afterwards, it said.
(Reporting by Michael Shields Editing by Michelle Martin)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.